Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-DOS47 with Vinorelbine/Cisplatin in Lung Adenocarcinoma
NCT03891173Phase 2Terminated
- Sponsor
- Helix BioPharma
- Start
- Feb 2019
- Primary completion
- May 2020
- Modality
- Antibody Fragments, Antibody-Drug Conjugates (ADCs), Replacement Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of L-DOS47 in lung adenocarcinoma (2 arms), sponsored by Helix BioPharma. Primary endpoint: Time to Disease Progression at 12 weeks. Started Feb 2019; status: terminated.
02
Drugs
L-DOS47
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03891173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891173.